Novo and Sanofi are among the investors that could exit the mineralisation disease therapy developer, which has filed to raise up to $86.3m.
Inozyme Pharma, a US-based mineralisation disorder drug developer backed by corporates Nan Fung, Novo and Sanofi, has filed for an $86.3m initial public offering on the Nasdaq Global Market.
Spun out of Yale University in 2015, Inozyme is targeting on rare, debilitating diseases caused by abnormal mineralisation and affecting soft tissue, the vascular system and the skeleton.
The company’s lead asset, INZ-701, aims to correct deficiencies in pathways responsible for conditions such as generalised arterial calcification of infancy, a…
Thierry Heles
Thierry Heles is editor-at-large of Global University Venturing and Global Corporate Venturing, and host of the Beyond the Breakthrough podcast.
